IgA Nephropathy, Lymphocyte Homing and IgA Class Switch

NCT01775527 | Completed

• 1 other identifier: I10 014
• Study Type: interventional
• Target: 72
• Locations: 1 country
• Sites: 1

Brief Summary

IgA nephropathy (IgAN) is the most common primary glomerulonephritis in the world and it represents an important cause of end-stage kidney failure. This disease was described as a distinct entity in 1968 by J Berger and N Hinglais. The aetiology and the pathogenesis remain still obscure. Clinical observations and immunisation studies indicate that IgAN represents a dysregulation of the immune system, rather than an intrinsic renal abnormality. Twenty years ago, some authors proposed the mucosa-bone marrow axis to explain the pathogenesis of the disease. Mucosal IgA plasmocytes are displaced and take up residence in systemic sites. The unusual characteristics featured by the IgA produced by these cells (charge, size, glycosylation) drive their accumulation, deposition and mesangial activation characteristic of IgAN. Evidence is emerging that altered lymphocyte homing may ultimately explain this aberrant localization.

Conditions

IgA Nephropathy

Outcome Measures

Primary Outcomes (1)

• The Primary Outcome Measure of this study is the level of expression of the molecules of intestinal localization.

  30 minutes

Secondary Outcomes (1)

• The secondary outcome measure is the level of expression of the homing molecules in lymphocytes B IgA memory

  30 minutes

Study Arms (1)

blood test

OTHER

Other: blood test

Interventions

blood test OTHER

blood test

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age \> 18 and \< 70 years
• Glomerular filtration rate (MDRD formula as simplified) \< 90 ml/mn and \> 30 ml/mn/1,73 m2
• Consent form signed

You may not qualify if:

• Patients with cirrhosis or chronic liver disease
• Patients with a history of Crohn's disease or celiac disease
• Patients who received treatment with corticosteroids or affiliates for six months
• Patients who received a live attenuated vaccine during the past 4 weeks
• Patients with a known infection such as HIV, hepatitis B or C
• Patients who presented with a serious infection during the last month
• Breastfeeding women
• Patients not affiliated with a social security scheme
• Under guardianship patient

Sponsors & Collaborators

• University Hospital, Limoges: lead

Study Sites (1)

University Hospital, Limoges

Limoges, 87 042, France

Location

MeSH Terms

Conditions

Glomerulonephritis, IGA

Interventions

Hematologic Tests

Condition Hierarchy (Ancestors)

Glomerulonephritis; Nephritis; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Autoimmune Diseases; Immune System Diseases

Intervention Hierarchy (Ancestors)

Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Investigative Techniques

Study Officials

• Ahmed Boumediene, doctor

  University Hospital, Limoges

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 18, 2013
• First Posted: January 25, 2013
• Study Start: February 1, 2013
• Primary Completion: February 1, 2014
• Study Completion: June 1, 2016
• Last Updated: August 22, 2016

Record last verified: 2012-11

Locations

FR (1)